Please assess the completion status of the following clinical trial:

Trial Title: Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF), documented by electrocardiography performed at screening or within the prior 6 months~* Indication for oral anticoagulation as assessed by CHA2DS2-VASc-Score (≥ 2)~* Severe to end-stage chronic kidney disease (eGFR \< 30 ml/min as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)~* 18 to 80 years, inclusive~* Life expectancy of at least 2 years~* Negative pregnancy test for women~* Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent~* Written informed consent~Exclusion Criteria:~* AF due to a reversible cause or a singular occurrence of AF~* Conditions other than AF that require anticoagulation~* Transient ischemic attack or stroke within previous 3 months~* A need for Aspirin (at a dose of \> 162.5 mg/day) or for both Aspirin and Clopidogrel/other antiplatelet drugs (daily administration) other than for clinical investigation~* Contraindications or allergies to vitamin K antagonists, Aspirin or Clopidogrel~* Previous closure (surgical, interventional) of the left atrial appendage (LAA)~* Previous closure of atrial septal defect (ASD) / persistent foramen ovale (PFO)~* Active internal bleeding~* Thrombocytopenia (\< 100,000 platelets/mm3)~* History of or planned organ transplantation~* Planned Mitra Clip or transcatheter aortic valve implantation (TAVI) intervention~* Planned cardiac surgery~* History of intracranial, intraocular or retroperitoneal bleeding~* Severe GI-bleeding within the last 3 months~* Hemorrhagic gastro-intestinal diseases (e.g., ulcerative colitis)~* History of or condition associated with increased bleeding risk~* Uncontrolled arterial hypertension~* Heparin-induced thrombocytopenia type II~* Known inherited coagulation disorders~* Severe liver dysfunction (spontaneous INR \> 1.5) or liver cirrhosis ≥ CHILD B~* Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)~* Women who are planning to become pregnant, or who are breastfeeding~* Active infection of any kind~Transesophageal echocardiography (TEE) Exclusion Criteria~* Intracardiac thrombus or dense spontaneous echo contrast as visualized by TEE (with use of sonovue in suspicious cases)~* Significant mitral valve stenosis~* Any congenital heart disease, including atrial septal defect~* Pericardial effusion during ECHO assessment of \> 2 mm~* Cardiac tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Left atrial appendage occlusion (Type: ACTIVE_COMPARATOR): Percutaneous left atrial appendage closure using the WATCHMAN device.
- OAC with a vitamin K antagonist (Type: NO_INTERVENTION): Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues